Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer

NCT01212627 is registered in ClinicalTrials.gov with Angela Taber MD as lead sponsor.

NCT NCT01212627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01212627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer
Lead sponsor
Angela Taber MD
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2010
Completion date
April 30, 2013
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer